Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies
A study found that outpatient observation cut hospital stays dramatically, with no adverse safety events reported. It also freed up inpatient beds and cut healthcare costs.
Clinical Scorecard: Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies
At a Glance
Category Detail
Condition Relapsed lymphoma and multiple myeloma Key Mechanisms T-cell redirecting therapies, including CAR T and bispecific T-cell engagers (BiTEs), enhance the immune system to combat cancer. Target Population Patients with relapsed lymphoma and multiple myeloma receiving T-cell redirecting therapies. Care Setting Outpatient monitoring at home.
Key Highlights
Outpatient observation significantly reduced hospital stays without adverse safety events. More than half of BiTE patients avoided hospitalization entirely. Structured outpatient model optimized inpatient bed utilization and reduced healthcare costs. Daily toxicity assessments and caregiver involvement were crucial for patient safety. The program can be easily replicated by other hospitals. Guideline-Based Recommendations
Diagnosis
Monitor patients receiving T-cell redirecting therapies for potential severe side effects. Management
Implement outpatient monitoring with caregiver support and daily assessments. Monitoring & Follow-up
Conduct daily toxicity assessments and maintain close communication with patients and caregivers. Risks
Potential severe side effects from overactive immune response. Patient & Prescribing Data
Patients receiving CAR T and BiTE therapies for blood cancers.
Outpatient monitoring is safe and effective, allowing for reduced hospital stays.
Clinical Best Practices
Ensure patients have a caregiver for monitoring during outpatient therapy. Educate patients and caregivers on warning signs and symptoms of toxicity. Facilitate close multidisciplinary collaboration within the treatment team. References
